Fundraising Fox

Pulmotect

Houston, US · 2 known investors

Pulmotect develops PUL-042, a clinical-stage inhaled therapeutic that stimulates the innate immune system in the lungs to protect against viral, bacterial, and fungal pathogens. The drug is being studied for preventing respiratory complications such as pneumonia and for improving outcomes in immunocompromised cancer patients, as well as populations with COPD, asthma, and seasonal infections.

BiotechHealthtech

Founders & leadership

CB
Colin BroomExecutive

Board

KS
Kumar SrinivasanBoard director
AV
Atul VaradhacharyBoard director
LE
Leo E. LinbeckBoard director
BS
Brenton ScottBoard director
MW
Mark WorschehBoard director
LL
Leo Linbeck IIIBoard director
MH
Magnus HookBoard director
BG
Bruce GivenBoard director

Investors · 2

Texas VenturesHoustonvia E. Scott Crist · inferred
Fannin Goldenrod HoldingsreportedHouston

Reported raises · per SEC filings

Form D private placements

$26.8M disclosed across 6 rounds · 2016–2024

▶$10.3MraisedSep 2024 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kumar SrinivasanDirector
  • Magnus HookDirector
  • Atul VaradhacharyDirector
  • Colin BroomExecutive Officer, Director
  • Bruce GivenDirector
  • Leo E. LinbeckDirector
  • Brenton ScottDirector
Amount sold
$10.3M
Proceeds to insiders
$726.8K
First sale
Aug 2024
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.7MraisedJan 2024 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kumar SrinivasanDirector
  • Brenton ScottExecutive Officer
  • Atul VaradhacharyDirector
  • Magnus HookDirector
  • Colin BroomExecutive Officer, Director
  • Bruce GivenDirector
  • Leo E. Linbeck IIIDirector
Amount sold
$3.7M
Finders' fees
$7.5K
Proceeds to insiders
$1.2M
Placement agents
16 Points LLC
First sale
Jan 2022
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedSep 2023 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce GivenDirector
  • William NossExecutive Officer
  • James GamettDirector
  • Colin BroomExecutive Officer, Director
  • Atul VaradhacharyDirector
  • Brenton ScottExecutive Officer
  • Kumar SrinivasanDirector
  • Leo E. Linbeck IIIDirector
  • Magnus HookDirector
Amount sold
$1.5M
First sale
May 2023
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.5MraisedMar 2021 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Brenton ScottExecutive Officer
  • Colin BroomExecutive Officer, Director
  • Kumar SrinivasanDirector
  • Mark BenedykDirector
  • Atul VaradhacharyDirector
  • Bruce GivenDirector
  • Leo Linbeck IIIDirector
  • Magnus HookDirector
Offering amount
$3.5M
Amount sold
$3.5M
Sales commissions
$17.6K
Placement agents
16 Points LLC
First sale
Mar 2021
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.1MraisedFeb 2020 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Brenton ScottExecutive Officer
  • Colin BroomExecutive Officer, Director
  • Kumar SrinivasanDirector
  • Bruce GivenDirector
  • Mark BenedykDirector
  • Leo Linbeck IIIDirector
  • Magnus HookDirector
  • Atul VaradhacharyDirector
Amount sold
$6.1M
First sale
Feb 2018
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedMay 2016 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Brenton ScottExecutive Officer, Promoter
  • Mark WorschehDirector
  • Bruce GivenDirector
  • Magnus HookDirector
  • Atul VaradhacharyDirector
  • Leo Linbeck IIIDirector
Offering amount
$2.5M
Amount sold
$1.8M
First sale
Apr 2016
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Pulmocide4 shared keywordsPulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis. Its lead investigational drug, opelconazole, is an inhaled antifungal agent in Phase 3 trials for patients with invasive pulmonary aspergillosis not responding to standard care.

Companies competing with Pulmotect for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Pulmotect do?
Pulmotect develops PUL-042, a clinical-stage inhaled therapeutic that stimulates the innate immune system in the lungs to protect against viral, bacterial, and fungal pathogens. The drug is being studied for preventing respiratory complications such as pneumonia and for improving outcomes in immunocompromised cancer patients, as well as populations with COPD, asthma, and seasonal infections.
Who are Pulmotect's investors?
Pulmotect's investors include Texas Ventures, Fannin Goldenrod Holdings.
How much funding has Pulmotect raised?
Pulmotect has disclosed $26.8M raised across 6 rounds.
Where is Pulmotect headquartered?
Pulmotect is headquartered in Houston, US.